DEVA Holding

DEVA Holding A.Ş. is a Turkish pharmaceutical manufacturer and marketer that has operated since 1958. Its core business covers the development, production, registration, and commercialization of human pharmaceutical products, supported by manufacturing and research capabilities in Turkey. The company also produces active pharmaceutical ingredients and has additional activities in veterinary medicines, medical ampoules, food supplements, inhalation products, and cologne. DEVA’s portfolio spans a broad range of dosage forms and therapeutic applications. Its manufacturing capabilities include tablets, capsules, syrups, creams, ointments, gels, drops, inhalation products, sterile medicines, antibiotics, hormonal products, and oncology products. The company operates three manufacturing facilities in Turkey with an aggregate annual production capacity of approximately 620 million units. The facilities are described as holding European Union Good Manufacturing Practice and United States Food and Drug Administration compliance approvals. Research and development is organized through DEVARGE. Its activities include pharmaceutical and analytical development, biotechnology, active pharmaceutical ingredient development, bioequivalence, stability work, scale-up, and manufacturing-process development. The R&D organization employs more than 400 people, according to the supplied company information. This structure allows DEVA to support both new product development and the industrialization of medicines for domestic and export markets. The company’s international business includes product registrations in Europe, North America, and other markets. In 2025, DEVA reportedly held 1,863 product registrations across 86 countries, with part of its international activity conducted under the Devatis brand. Its specialist operating brands include VETAŞ for veterinary pharmaceutical activities and Boğaziçi Kolonyaları for cologne products. A majority stake in DEVA Holding was acquired by EastPharma in 2006. DEVA remains listed on Borsa Istanbul and is led by chairman and chief executive officer Philipp Haas. As of 2025, the company reported more than 675 products across 15 therapeutic areas. IQVIA data cited in the company’s annual reporting placed DEVA third in the Turkish pharmaceutical market by unit sales in 2025, with a 4.5% unit-sales share. These figures describe market position by units rather than revenue and should not be interpreted as a valuation or sales figure.

DEVA Holding is a Turkish pharmaceutical company whose operating history dates to 1958. Its development has centered on the production and marketing of human medicines, while progressively incorporating associated capabilities such as active pharmaceutical ingredient production, research and development, regulatory registration, and international commercialization. The available reference material does not identify the company’s founder or provide a detailed account of its earliest corporate formation, so those aspects remain unspecified. The company’s principal industrial base is in Turkey. DEVA operates three manufacturing facilities with a combined annual capacity of approximately 620 million units. Its production platform covers a wide variety of pharmaceutical forms, including solid oral medicines such as tablets and capsules; liquid products such as syrups and drops; topical products including creams, ointments, and gels; inhalation products; sterile products; antibiotics; hormonal medicines; and oncology products. The same manufacturing organization also supports production of active pharmaceutical ingredients, veterinary medicines, and medical ampoules. The facilities are reported to have European Union Good Manufacturing Practice and United States Food and Drug Administration compliance approvals. Research and development is conducted through DEVARGE. The organization’s work includes pharmaceutical formulation and analytical development, biotechnology, active pharmaceutical ingredient development, bioequivalence, stability studies, scale-up, and manufacturing-process development. With more than 400 employees in its R&D organization according to the supplied material, DEVA presents research and industrial manufacturing as integrated parts of its business rather than relying solely on external licensing or distribution. A major ownership turning point occurred in 2006, when EastPharma acquired a majority stake in DEVA Holding. The transaction placed the Turkish manufacturer within EastPharma’s ownership structure while DEVA continued operating under its own corporate identity and remained listed on Borsa Istanbul. The available sources do not provide the transaction value, the precise percentage acquired, or a full account of the ownership changes that followed; those details are therefore omitted. DEVA’s business subsequently developed an international dimension. The company operates in Turkey and has activities in Europe, North America, and other international markets. Some of this international activity is conducted through the Devatis brand. By 2025, DEVA was reported to have 1,863 product registrations in 86 countries. Its portfolio also included more than 675 products across 15 therapeutic areas, illustrating the breadth of its registration and manufacturing platform. The company maintains adjacent healthcare and consumer-product activities through named operating brands. VETAŞ is associated with veterinary pharmaceuticals, while Boğaziçi Kolonyaları is associated with cologne products. These activities broaden DEVA’s scope beyond human prescription and over-the-counter medicines, although pharmaceuticals remain its defining business. As of 2025, Philipp Haas was identified as DEVA Holding’s chairman and chief executive officer. IQVIA data cited in the company’s annual report placed DEVA third in the Turkish pharmaceutical market by unit sales, with a 4.5% share. This indicator reflects the number of units sold and does not establish the company’s revenue ranking, profitability, or market capitalization.

1. 2025Broad product and international registration base reported

   DEVA was reported to have more than 675 products in 15 therapeutic areas and 1,863 product registrations across 86 countries.

   Source
2. 2025Third-place Turkish unit-sales ranking reported

   IQVIA data cited in the company’s annual reporting ranked DEVA third in Turkey by pharmaceutical unit sales, with a 4.5% unit-sales share.

   Source
3. 2006EastPharma acquires a majority stake

   EastPharma acquired a majority interest in DEVA Holding, becoming its controlling shareholder while the company continued as a listed Turkish pharmaceutical business.

   Source
4. 1958Company begins operating

   DEVA Holding’s operating history in the Turkish pharmaceutical sector dates to 1958.

   Source

A vertically capable Turkish pharmaceutical manufacturer combining domestic market scale, broad dosage-form production, in-house research and development, and international registration and export activity.

• Human pharmaceutical medicinesHuman pharmaceuticals

  DEVA’s core portfolio consists of human medicines spanning 15 therapeutic areas. The company manufactures multiple dosage forms, including tablets, capsules, syrups, creams, ointments, gels, drops, inhalation products, sterile preparations, antibiotics, hormonal medicines, and oncology products. The portfolio includes products developed for the Turkish market and products registered internationally.

• Active pharmaceutical ingredientsPharmaceutical ingredients

  DEVA manufactures active pharmaceutical ingredients and conducts related development work through its R&D organization. Its capabilities include active-ingredient development, analytical development, scale-up, stability work, and manufacturing-process development.

• DevatisInternational pharmaceutical brand

  Devatis is the brand under which part of DEVA Holding’s international pharmaceutical activity is conducted. The company’s international business includes product registrations in Europe, North America, and other markets.

• VETAŞVeterinary pharmaceuticals

  VETAŞ is DEVA Holding’s operating brand for veterinary pharmaceutical activities. The available reference material identifies the brand and its sector but does not specify individual veterinary product names.

• Boğaziçi KolonyalarıCologne and personal care

  Boğaziçi Kolonyaları is associated with DEVA Holding’s cologne manufacturing activity. The available sources identify the product category and brand but do not provide a detailed product chronology.

• Medical ampoulesMedical packaging and dosage forms

  Medical ampoules are among the products manufactured within DEVA Holding’s broader pharmaceutical production platform, alongside sterile medicines and other specialized dosage forms.

• Food supplementsNutritional products

  Food supplements form part of DEVA Holding’s activities outside its principal human-medicines business. The supplied material does not identify specific supplement ranges or launch dates.

• 2006Majority stake acquisition by EastPharmaM&A

  EastPharma acquired a majority stake in DEVA Holding as part of the company’s ownership development.

  What changed. EastPharma became the controlling shareholder of the Turkish pharmaceutical company.

  Aftermath. DEVA continued operating as a pharmaceutical manufacturer and remained listed on Borsa Istanbul. The supplied sources do not state the transaction value or detailed post-acquisition integration measures.

  Source

• 2025DEVA Holding reported more than 675 products across 15 therapeutic areas

  Company information cited in the supplied reference material described DEVA Holding as having more than 675 products across 15 therapeutic areas.

  Other
  Source
• 2025DEVA Holding ranked third in Turkey by pharmaceutical unit sales

  IQVIA data cited in DEVA’s annual reporting placed the company third in the Turkish pharmaceutical market by unit sales, with a reported 4.5% unit-sales share.

  Other
  Source
• 2025DEVA Holding expanded its international registration footprint

  The company was reported to hold 1,863 product registrations across 86 countries, supporting international activity conducted partly through the Devatis brand.

  Other
  Source

1. DEVA Holding A.Ş.
2. DEVA Holding official English website